{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:57:18Z","timestamp":1792645038590,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.resinv.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:44:47Z","timestamp":1749671087000},"page":"726-733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world effectiveness of budesonide\/glycopyrronium\/formoterol fumarate metered dose inhaler on symptoms and quality of life in patients with COPD: EBISU study"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-9191","authenticated-orcid":false,"given":"Shigeo","family":"Muro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-7759","authenticated-orcid":false,"given":"Soichiro","family":"Hozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-7048","authenticated-orcid":false,"given":"Hisatoshi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9131-933X","authenticated-orcid":false,"given":"Yuri","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-1056","authenticated-orcid":false,"given":"Takehiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-4229","authenticated-orcid":false,"given":"Tomotaka","family":"Kawayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.05.007_bib1","series-title":"Chronic obstructive pulmonary disease","author":"Agarwal","year":"2023"},{"key":"10.1016\/j.resinv.2025.05.007_bib2","series-title":"GOLD Report. Global strategy for prevention, diagnosis and management of COPD: 2024 Report","year":"2024"},{"key":"10.1016\/j.resinv.2025.05.007_bib3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.resinv.2023.08.007","article-title":"Management goals and stable phase management of patients with chronic obstructive pulmonary disease in the Japanese respiratory society guideline for the management of chronic obstructive pulmonary disease 2022 (6th edition)","volume":"61","author":"Shibata","year":"2023","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.05.007_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.resinv.2021.01.007","article-title":"The Japanese respiratory society guidelines for the management of cough and sputum (digest edition)","volume":"59","author":"Mukae","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.05.007_bib5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.pulmoe.2022.04.004","article-title":"Impact of acute exacerbations of COPD on patients' health status beyond pulmonary function: a scoping review","volume":"29","author":"Machado","year":"2023","journal-title":"Pulmonology"},{"key":"10.1016\/j.resinv.2025.05.007_bib6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2025.05.007_bib7","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.2147\/COPD.S220850","article-title":"Efficacy and safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD: a subgroup analysis of the KRONOS study","volume":"14","author":"Ichinose","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.05.007_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.05.007_bib9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.05.007_bib10","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2025.05.007_bib11","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel-group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2025.05.007_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12931-021-01777-x","article-title":"Triple versus LAMA\/LABA combination therapy for patients with COPD: a systematic review and meta-analysis","volume":"22","author":"Koarai","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.05.007_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2147\/COPD.S153295","article-title":"Changes in ventilation-perfusion during and after an COPD exacerbation: an assessment using fluid dynamic modeling","volume":"13","author":"Hajian","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.05.007_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.alit.2023.08.003","article-title":"Exacerbation rates in Japanese patients with obstructive lung disease: a subanalysis of the prospective, observational NOVELTY study","volume":"73","author":"Kawayama","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2025.05.007_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD Assessment Test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J"},{"issue":"Suppl B","key":"10.1016\/j.resinv.2025.05.007_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George\u2019s Respiratory Questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.05.007_bib17","first-page":"751","article-title":"The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest (Am Coll Chest Physicians)"},{"key":"10.1016\/j.resinv.2025.05.007_bib18","first-page":"99","article-title":"The MCID of the transition dyspnea index is a total score of one unit","volume":"2","author":"Mahler","year":"2005","journal-title":"COPD (Monticello (Sullivan County, N Y))"},{"key":"10.1016\/j.resinv.2025.05.007_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/jamp.2015.1212","article-title":"Validation of the \u2018Test of the Adherence to Inhalers\u2019 (TAI) for asthma and COPD patients","volume":"29","author":"Plaza","year":"2016","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.resinv.2025.05.007_bib20","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2147\/COPD.S181938","article-title":"Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan","volume":"13","author":"Oishi","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.05.007_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.resinv.2022.10.010","article-title":"Chronic obstructive pulmonary disease features in patients visiting primary respiratory clinic and tertiary hospital in Japan","volume":"61","author":"Terada","year":"2023","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.05.007_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/COPD.S385186","article-title":"Real-world evidence on the diagnostic and clinical characteristics of asthma in Japanese patients with COPD: the ACO Japan Cohort Study","volume":"18","author":"Hashimoto","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.05.007_bib23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.05.007_bib24","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.2147\/COPD.S382405","article-title":"Effectiveness of extrafine single inhaler triple therapy in chronic obstructive pulmonary disease (COPD) in Germany - the TriOptimize study","volume":"17","author":"Gessner","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.05.007_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/COPD.S427770","article-title":"Real-world effectiveness of fluticasone furoate\/umeclidinium\/vilanterol once-daily single-inhaler triple therapy for symptomatic COPD: the ELLITHE non-interventional trial","volume":"19","author":"Beeh","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.05.007_bib26","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2147\/COPD.S474354","article-title":"The real-world efficacy of fixed triple inhalation therapy in the treatment of moderate COPD patients (RATIONALE Study)","volume":"19","author":"S\u00fcdi","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.05.007_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/COPD.S274846","article-title":"Consistent pulmonary drug delivery with whole lung deposition using the Aerosphere inhaler: a review of the evidence","volume":"16","author":"Usmani","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.05.007_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12931-021-01772-2","article-title":"Functional respiratory imaging assessment of budesonide\/glycopyrrolate\/formoterol fumarate and glycopyrrolate\/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids","volume":"22","author":"van den Berge","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.05.007_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12931-023-02534-y","article-title":"Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging","volume":"24","author":"Usmani","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.05.007_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.05.007_bib31","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.2147\/COPD.S280464","article-title":"The relationship between the \u201cAdherence Starts with Knowledge-20\u201d questionnaire and clinical factors in patients with COPD: a multi-center, cross-sectional study","volume":"15","author":"Akimoto","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:57:17Z","timestamp":1762606637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2212534525000711"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.05.007","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of budesonide\/glycopyrronium\/formoterol fumarate metered dose inhaler on symptoms and quality of life in patients with COPD: EBISU study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}